key: cord-0899829-e5qav9lt
authors: Dhand, Abhay; Lobo, Stephen A.; Wolfe, Kevin; Feola, Nicholas; Nabors, Christopher
title: Bamlanivimab for treatment of COVID‐19 in solid organ transplant recipients: Early single‐center experience
date: 2021-02-17
journal: Clin Transplant
DOI: 10.1111/ctr.14245
sha: d8b667187fe47f64562b95f873183d20e3ac13e9
doc_id: 899829
cord_uid: e5qav9lt

nan

at Westchester Medical Center from March-August 2020, 63% required hospitalization, 19% required ICU stay, 14% required mechanical ventilation, and 12% died. In a prior study of 482 SOT recipients with COVID-19 from more than 50 centers, a significant number of patients required hospitalization (78%), mechanical ventilation (31%) and 20.5% patients died during 28-day follow-up. 2 Bamlanivimab is a recombinant neutralizing human monoclonal antibody which binds to the viral spike protein, blocking attachment to the human angiotensin-converting enzyme-2 receptor.

Bamlanivimab received Emergency Use Authorization (EUA) by the US Food and Drug Administration (FDA) for the treatment of patients with mild-to-moderate COVID-19 who are at high risk for progression to hospitalization. 3 Compared to placebo, Bamlanivimab reduced hospitalization and emergency department visits in highrisk study patients (2.9% vs 10.1%) but did not show benefit among patients who were hospitalized with COVID-19. 4, 5 Since its approval, we started using Bamlanivimab routinely for our adult SOT patients and we present our early experience with its use in patients with at least 14-day follow-up post-infusion. Between November and early December 2020, of 12 adult SOT patients diagnosed with COVID-19, 10 met current FDA EUA criteria for Bamlanivimab administration (6-kidney, 2-liver, 1-liver/kidney, and 1-heart) while 2 patients did not meet the criteria (1 required hospitalization, 1 was asymptomatic). All ten patients had mild-moderate symptoms, did not require supplemental oxygen and/or hospitalization from COVID-19, and 

COVID-19 in solid organ transplant recipients: Initial report from the US Epicenter

COVID-19 in solid organ transplant: a multi-center cohort study

Fact sheet for healthcare providers: emergency use authorization (EUA) of bamlanivimab

SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19

A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19